Dec 5 (Reuters) - Sanofi is considering a bid for Swiss biotech company Actelion, rivaling an offer made by U.S. healthcare company Johnson & Johnson, Bloomberg reported, citing people familiar with the matter.
J&J said last month it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, which was then valued at about $20 billion. (bloom.bg/2h0cgBl)
Lung disease specialist Actelion has confirmed the J&J offer but has warned there is no certainty of a deal.
Sanofi, J&J and Actelion were not immediately available for comments. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)